Success Metrics

Clinical Success Rate
100.0%

Based on 22 completed trials

Completion Rate
100%(22/22)
Active Trials
11(27%)
Results Posted
45%(10 trials)

Phase Distribution

Ph early_phase_1
1
2%
Ph not_applicable
3
7%
Ph phase_1
2
5%
Ph phase_2
24
59%
Ph phase_3
8
20%
Ph phase_4
1
2%

Phase Distribution

3

Early Stage

24

Mid Stage

9

Late Stage

Phase Distribution39 total trials
Early Phase 1First-in-human
1(2.6%)
Phase 1Safety & dosage
2(5.1%)
Phase 2Efficacy & side effects
24(61.5%)
Phase 3Large-scale testing
8(20.5%)
Phase 4Post-market surveillance
1(2.6%)
N/ANon-phased studies
3(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

22 of 22 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

11

trials recruiting

Total Trials

41

all time

Status Distribution
Active(15)
Completed(22)
Other(4)

Detailed Status

Completed22
Active, not recruiting7
Not yet recruiting4
Recruiting4
unknown4

Development Timeline

Analytics

Development Status

Total Trials
41
Active
11
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (2.6%)
Phase 12 (5.1%)
Phase 224 (61.5%)
Phase 38 (20.5%)
Phase 41 (2.6%)
N/A3 (7.7%)

Trials by Status

completed2254%
not_yet_recruiting410%
recruiting410%
unknown410%
active_not_recruiting717%

Recent Activity

Clinical Trials (41)

Showing 20 of 41 trialsScroll for more
NCT04630145Phase 2

A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

Completed
NCT03828201Phase 2

Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB

Active Not Recruiting
NCT06192160Phase 2

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting
NCT06568484Phase 2

Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

Not Yet Recruiting
NCT07485010Phase 2

Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

Not Yet Recruiting
NCT05556746Phase 2

Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB

Active Not Recruiting
NCT06441006Phase 2

Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

Recruiting
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT05382312Phase 2

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis

Completed
NCT07198685Not Applicable

6 Months of Bedaquiline(BDQ), Delamanid(DLM), Linezolid(LZD) and Levofloxacin(LFX) in RR-TB Patients in Hubei Province

Not Yet Recruiting
NCT05766267Phase 2

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Active Not Recruiting
NCT02333799Phase 3

A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB

Completed
NCT02906007Phase 1

Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV

Completed
NCT06649721Phase 3

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort

Active Not Recruiting
NCT07126639Not Applicable

A Study on the Short-course Treatment Regimen Containing Pretomanid for Drug-resistant Tuberculosis

Not Yet Recruiting
NCT04310930Phase 2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting
NCT05824871Phase 3

A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients

Recruiting
NCT05686356Phase 2

A Pan-TB Regimen Targeting Host and Microbe

Active Not Recruiting
NCT06081361Phase 3

Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis:Contezolid, Delamanid and Bedaquiline Cohort

Active Not Recruiting
NCT06058299Phase 2

Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
41